An Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Extended Release Oral TTI-0102 (as a potential treatment for COVID-19) compared to Cystagon in Healthy Adult Male and Female Volunteers.
Latest Information Update: 16 Feb 2021
At a glance
- Drugs TTI-0102 (Primary) ; Mercaptamine bitartrate
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- Sponsors Thiogenesis Therapeutics
- 16 Feb 2021 Recruitment completion is expected on 25May2021 according to ACTRN12621000131853p.
- 15 Feb 2021 New trial record